Cargando…

Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience

Meningococcal diseases are serious threats to global health, and new vaccines specifically tailored to meet the age-related needs of various geographical areas are required. This paper focuses on the meningococcal conjugate vaccines developed by GSK Biologicals. Two combined conjugate vaccines were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miller, Jacqueline M., Mesaros, Narcisa, Van Der Wielen, Marie, Baine, Yaela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE-Hindawi Access to Research 2011
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170757/ https://www.ncbi.nlm.nih.gov/pubmed/21991444 http://dx.doi.org/10.4061/2011/846756

Ejemplares similares

Immunogenicity and safety of the Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine co-administered with human rotavirus, hepatitis A and 13-valent pneumococcal conjugate vaccines: results from a phase III, randomized, multicenter study in infants
por: Klein, Nicola P., et al.
Publicado: (2018)

Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children
por: Knuf, Markus, et al.
Publicado: (2012)

Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Conjugate Vaccines
por: Tejedor, Juan Carlos, et al.
Publicado: (2016)

The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: A randomized, controlled non-inferiority study
por: Dbaibo, Ghassan, et al.
Publicado: (2012)

Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10–25 Years of Age
por: Halperin, Scott A., et al.
Publicado: (2014)

The investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults
por: Reyes, Mari Rose Aplasca-De Los, et al.
Publicado: (2012)

Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents
por: Quiambao, Beatriz P., et al.
Publicado: (2017)

Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine
por: Vesikari, Timo, et al.
Publicado: (2015)

Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents
por: Quiambao, Beatriz P., et al.
Publicado: (2016)

Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2–10-year-old children: results of an open, randomised, controlled study
por: Knuf, Markus, et al.
Publicado: (2013)

Immunogenicity and Safety of a Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine (MenACWY-TT) Administered to Adults Aged 56 Years and Older: Results of an Open-Label, Randomized, Controlled Trial
por: Dbaibo, Ghassan, et al.
Publicado: (2013)

A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2–10 years
por: Vesikari, Timo, et al.
Publicado: (2012)

Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers
por: Vesikari, Timo, et al.
Publicado: (2012)

Technical Development of a New Meningococcal Conjugate Vaccine
por: Frasch, Carl E., et al.
Publicado: (2015)

Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study
por: Borja-Tabora, Charissa, et al.
Publicado: (2013)

Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine
por: Quiambao, Beatriz, et al.
Publicado: (2020)

Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial
por: Borja-Tabora, Charissa Fay Corazon, et al.
Publicado: (2015)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-naïve and meningococcal C conjugate vaccine-primed toddlers: a phase III randomised study
por: van der Vliet, D., et al.
Publicado: (2021)

Using the tetravalent meningococcal polysaccharide-protein conjugate vaccine in the prevention of meningococcal disease
por: Kimmel, Sanford R
Publicado: (2008)

Meningococcal conjugate vaccines: optimizing global impact
por: Terranella, Andrew, et al.
Publicado: (2011)

Factors contributing to the immunogenicity of meningococcal conjugate vaccines
por: Bröker, Michael, et al.
Publicado: (2016)

Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands
por: Kaaijk, Patricia, et al.
Publicado: (2012)

Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease
por: Hedari, Carine P, et al.
Publicado: (2014)

The Diversity of Meningococcal Carriage Across the African Meningitis Belt and the Impact of Vaccination With a Group A Meningococcal Conjugate Vaccine
Publicado: (2015)

Meningococcal Carriage among Adolescents after Mass Meningococcal C Conjugate Vaccination Campaigns in Salvador, Brazil
por: Nunes, Amélia Maria Pithon Borges, et al.
Publicado: (2016)

Meningococcal disease before and after the introduction of meningococcal serogroup C conjugate vaccine. Federal District, Brazil
por: Tauil, Márcia de Cantuária, et al.
Publicado: (2014)

A Mouse Immunogenicity Model for the Evaluation of Meningococcal Conjugate Vaccines
por: Arunachalam, Arun B., et al.
Publicado: (2022)

Preclinical development of the quadrivalent meningococcal (ACYW) tetanus toxoid conjugate vaccine, MenQuadfi®
por: Kensinger, Richard, et al.
Publicado: (2022)

Ethical Challenges and Lessons Learned During the Clinical Development of a Group A Meningococcal Conjugate Vaccine
por: Martellet, Lionel, et al.
Publicado: (2015)

Eliminating Meningococcal Epidemics From the African Meningitis Belt: The Case for Advanced Prevention and Control Using Next-Generation Meningococcal Conjugate Vaccines
por: Alderson, Mark R, et al.
Publicado: (2019)

The safety profile of Haemophilus influenzae type b–Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY)
por: Rinderknecht, Stephen, et al.
Publicado: (2012)

Continuing Effectiveness of Serogroup A Meningococcal Conjugate Vaccine, Chad, 2013
por: Gamougam, Kadidja, et al.
Publicado: (2015)

Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children
por: Sow, Samba O., et al.
Publicado: (2023)

Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial
por: Knuf, Markus, et al.
Publicado: (2022)

Safety Monitoring in Group A Meningococcal Conjugate Vaccine Trials: Description, Challenges, and Lessons
por: Enwere, Godwin C., et al.
Publicado: (2015)

Meningococcal Meningitis Outbreaks in the African Meningitis Belt After Meningococcal Serogroup A Conjugate Vaccine Introduction, 2011–2017
por: Fernandez, Katya, et al.
Publicado: (2019)

Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study
por: Ohm, Milou, et al.
Publicado: (2021)

Control of meningococcal meningitis with meningococcal vaccines.
por: Artenstein, M. S.
Publicado: (1975)

Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine
por: van Ravenhorst, Mariëtte B., et al.
Publicado: (2018)

Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine
por: Watle, Sara Viksmoen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lr6epse5rq1upovljctj0kkt8q